Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose of Review: We reviewed recent diagnostic and therapeutic progress in chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML). We summarized recent genetic data that may guide future efforts towards implementing risk-adapted therapy based on mutational profile and improving disease control and survival of affected patients. Recent Findings: Recent genetic data in CNL and aCML prompted modifications to the World Health Organization (WHO) diagnostic criteria, which have improved our understanding of how CNL and aCML are different diseases despite sharing common findings of peripheral granulocytosis and marrow myeloid hyperplasia. The overlap of recurrently mutated genes between aCML and CMML support considering CSF3R-T618I mutated cases as a distinct entity, either as CNL or CNL with dysplasia. Ongoing preclinical and clinical studies will help to further inform the therapeutic approach to these diseases. Summary: Our understanding of CNL and aCML has greatly advanced over the last few years. This will improve clarity for the diagnosis of these diseases, provide a strategy for risk stratification, and guide risk-adapted therapy.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalCurrent Hematologic Malignancy Reports
DOIs
StateAccepted/In press - Oct 6 2017

Fingerprint

Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
Leukemia, Neutrophilic, Chronic
Therapeutics
Hyperplasia
Bone Marrow
Survival

Keywords

  • Atypical chronic myelogenous leukemia
  • Chronic neutrophilic leukemia
  • Colony-stimulating factor 3 receptor (CSF3R)
  • JAK-STAT signaling
  • Myelodysplasia/myeloproliferative neoplasm (MDS/MPN)

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

@article{3eeb96c7caf4410b8473166863382527,
title = "Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia",
abstract = "Purpose of Review: We reviewed recent diagnostic and therapeutic progress in chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML). We summarized recent genetic data that may guide future efforts towards implementing risk-adapted therapy based on mutational profile and improving disease control and survival of affected patients. Recent Findings: Recent genetic data in CNL and aCML prompted modifications to the World Health Organization (WHO) diagnostic criteria, which have improved our understanding of how CNL and aCML are different diseases despite sharing common findings of peripheral granulocytosis and marrow myeloid hyperplasia. The overlap of recurrently mutated genes between aCML and CMML support considering CSF3R-T618I mutated cases as a distinct entity, either as CNL or CNL with dysplasia. Ongoing preclinical and clinical studies will help to further inform the therapeutic approach to these diseases. Summary: Our understanding of CNL and aCML has greatly advanced over the last few years. This will improve clarity for the diagnosis of these diseases, provide a strategy for risk stratification, and guide risk-adapted therapy.",
keywords = "Atypical chronic myelogenous leukemia, Chronic neutrophilic leukemia, Colony-stimulating factor 3 receptor (CSF3R), JAK-STAT signaling, Myelodysplasia/myeloproliferative neoplasm (MDS/MPN)",
author = "Kim-Hien Dao and Jeffrey Tyner and Jason Gotlib",
year = "2017",
month = "10",
day = "6",
doi = "10.1007/s11899-017-0413-y",
language = "English (US)",
pages = "1--10",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",

}

TY - JOUR

T1 - Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia

AU - Dao, Kim-Hien

AU - Tyner, Jeffrey

AU - Gotlib, Jason

PY - 2017/10/6

Y1 - 2017/10/6

N2 - Purpose of Review: We reviewed recent diagnostic and therapeutic progress in chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML). We summarized recent genetic data that may guide future efforts towards implementing risk-adapted therapy based on mutational profile and improving disease control and survival of affected patients. Recent Findings: Recent genetic data in CNL and aCML prompted modifications to the World Health Organization (WHO) diagnostic criteria, which have improved our understanding of how CNL and aCML are different diseases despite sharing common findings of peripheral granulocytosis and marrow myeloid hyperplasia. The overlap of recurrently mutated genes between aCML and CMML support considering CSF3R-T618I mutated cases as a distinct entity, either as CNL or CNL with dysplasia. Ongoing preclinical and clinical studies will help to further inform the therapeutic approach to these diseases. Summary: Our understanding of CNL and aCML has greatly advanced over the last few years. This will improve clarity for the diagnosis of these diseases, provide a strategy for risk stratification, and guide risk-adapted therapy.

AB - Purpose of Review: We reviewed recent diagnostic and therapeutic progress in chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML). We summarized recent genetic data that may guide future efforts towards implementing risk-adapted therapy based on mutational profile and improving disease control and survival of affected patients. Recent Findings: Recent genetic data in CNL and aCML prompted modifications to the World Health Organization (WHO) diagnostic criteria, which have improved our understanding of how CNL and aCML are different diseases despite sharing common findings of peripheral granulocytosis and marrow myeloid hyperplasia. The overlap of recurrently mutated genes between aCML and CMML support considering CSF3R-T618I mutated cases as a distinct entity, either as CNL or CNL with dysplasia. Ongoing preclinical and clinical studies will help to further inform the therapeutic approach to these diseases. Summary: Our understanding of CNL and aCML has greatly advanced over the last few years. This will improve clarity for the diagnosis of these diseases, provide a strategy for risk stratification, and guide risk-adapted therapy.

KW - Atypical chronic myelogenous leukemia

KW - Chronic neutrophilic leukemia

KW - Colony-stimulating factor 3 receptor (CSF3R)

KW - JAK-STAT signaling

KW - Myelodysplasia/myeloproliferative neoplasm (MDS/MPN)

UR - http://www.scopus.com/inward/record.url?scp=85030671757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030671757&partnerID=8YFLogxK

U2 - 10.1007/s11899-017-0413-y

DO - 10.1007/s11899-017-0413-y

M3 - Article

C2 - 28983816

AN - SCOPUS:85030671757

SP - 1

EP - 10

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

ER -